Bone loss and the aromatase inhibitors.
The increasing use of systemic adjuvant therapies has considerably improved the prognosis from early breast cancer. However, some of these therapies affect bone metabolism, resulting in osteoporosis. Aromatase inhibitors lower circulating oestrogen levels to almost unrecordable levels in postmenopausal women, predisposing them to bone loss with an increase in fracture risk. Ongoing clinical trials are favouring the use of the aromatase inhibitors over tamoxifen and this may advocate greater use of these drugs in the future. Strategies for the identification and management of treatment-induced bone loss are currently being defined.
Lester
J
J
Academic Unit of Clinical Oncology, Cancer Research Centre, Weston Park Hospital, Sheffield S10 2SJ, UK.
Coleman
R
R
D047072:Aromatase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D001862:Bone Resorption / Q000139:chemically induced* / Q000188:drug therapy; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D050723:Fractures, Bone / Q000139:chemically induced; D006801:Humans; D010024:Osteoporosis / Q000139:chemically induced; D017698:Postmenopause; D012307:Risk Factors
D047072:Aromatase Inhibitors